Odyssey Therapeutics Q2 2026: Cash Runway Extended to H2 2028, OD-001 Phase 2a Costs Drive R&D Increase
ODTX sits 46% above its 52-week low of $15.1.
Summary
Odyssey Therapeutics reported Q2 2026 net loss of $52.8M, with $433.1M in cash providing runway into H2 2028. R&D spend increased to $36.2M, driven by the OD-001 Phase 2a trial. A non-cash $8.7M charge from contingent consideration revaluation was recorded.
Key Events · Earnings and Guidance · ODTX
-
Cash Runway Extended to H2 2028
Cash, cash equivalents, and marketable securities totaled $433.1 million as of June 30, 2026, sufficient to fund operations into the second half of 2028.
-
Q2 2026 Net Loss of $52.8M
Net loss for the quarter was $52.8 million, compared to $41.2 million in Q2 2025, driven by higher R&D expenses and a non-cash contingent consideration charge.
-
R&D Expenses Rise on OD-001 Trial
Research and development expenses increased to $36.2 million in Q2 2026, up from $30.2 million a year ago, primarily due to costs associated with the ongoing OD-001 Phase 2a monotherapy trial.
-
Non-Cash Contingent Consideration Charge
A non-cash expense of $8.7 million was recorded from the change in fair value of contingent consideration related to the Rahko acquisition, reflecting updated assumptions post-IPO.
Analysis · ODTX · Life Sciences
Odyssey Therapeutics reported Q2 2026 results with a net loss of $52.8 million, bringing the six-month loss to $91.1 million. The company ended the quarter with $433.1 million in cash and marketable securities, extending its runway into the second half of 2028 — a critical survival metric for a clinical-stage biotech with no product revenue. R&D expenses rose to $36.2 million, driven by the ongoing OD-001 Phase 2a trial in ulcerative colitis, the company's lead asset. A non-cash $8.7 million charge from the revaluation of contingent consideration tied to the Rahko acquisition reflects the impact of the recent IPO on liability fair values, not a cash outflow. With no collaboration revenue recognized in the quarter, the company is entirely dependent on its capital reserves to fund operations. The filing confirms the company's post-IPO financial position and development progress, but the lack of near-term revenue and increasing R&D spend underscore the need for continued execution on clinical milestones.
At the time of this filing, ODTX was trading at $21.99 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $1B. The 52-week trading range was $15.10 to $21.41. This filing was assessed with neutral market sentiment and an importance score of 7 out of 10.